Abstract: The disclosed system may include an enclosure that is configured to house internal electrical components disposed on a printed circuit board (PCB). The system may also include a first antenna feed that is electrically connected to the PCB, to the enclosure, and to a radiating coupling arm configured for wireless communication in a first wireless communication band. The system may further include a second antenna feed that is electrically connected to the PCB and to an antenna configured for wireless communication in a second, different wireless communication band. The system may also include a first grounding leg that forms an electrical ground between the PCB and the enclosure, and a second, switchable grounding leg positioned away from the first grounding leg. This switchable grounding leg may provide a controllable electrical ground between the PCB and the enclosure. Various other methods and apparatuses are also disclosed.

Abstract: A battery module includes at least two rows of battery cells stacked together along the width direction of the battery cells, the at least two rows of battery cells comprising a first row of battery cells and a second row of battery cells that are adjacent to each other. The first row of battery cells and the second row of battery cells include a plurality of battery cells in total, where some of the battery cells in the plurality of battery cells have different lengths from the remaining battery cells. Along the width direction of the battery cells, a centerline along the length direction of at least one battery cell in the first row of battery cells is not collinear with a centerline along the length direction of at least one battery cell in the second row of battery cells.

Abstract: This application provides an electrode assembly, a battery cell, a battery, and an electric apparatus, and pertains to the field of battery technologies. The electrode assembly may include a negative electrode plate and a positive electrode plate. The negative electrode plate may include a negative electrode active substance layer, and a first electrolyte storage trough may be disposed on the negative electrode active substance layer. The positive electrode plate may include a positive electrode active substance layer, the positive electrode active substance layer and the negative electrode active substance layer may be disposed opposite each other in a first direction, and a second electrolyte storage trough may be disposed on the positive electrode active substance layer, the second electrolyte storage trough and the first electrolyte storage trough being disposed opposite each other in the first direction.

Abstract: A gas-exhausting apparatus includes a gas-exhausting body and a gas-exhausting mechanism. The gas-exhausting mechanism includes a connecting assembly and a gas-ventilating member. The connecting assembly includes first and second connecting members. The first connecting member is provided with a first through hole for communicating with an inside of the battery cell. The second connecting member is provided with a second through hole for communicating with an outside of the battery cell. The first connecting member is configured to attach to a surface of the gas-ventilating member facing the inside of the battery cell. The second connecting member is configured to attach to a surface of the gas-ventilating member facing away from the inside of the battery cell. An orthographic projection of the first through hole on the gas-ventilating member and an orthographic projection of the second through hole on the gas-ventilating member are arranged to be staggered from each other.

Abstract: Provided is a method for producing a target DNA sequence and a cloning vector. The method includes the step of amplifying and extracting a DNA construct in a host cell, and a three-step thermostatic enzyme reaction step of protelomerase-IIS type restriction endonuclease and/or meganuclease-DNA exonuclease catalysis, wherein the construct is autonomously replicated and contains (a) one or more IIS type restriction endonuclease and/or meganuclease recognition sequences; (b) the target DNA sequence; and (c) protelomerase recognition sequences at lateral wings of two ends of the target DNA sequence.

Abstract: An assembled subway station and a construction method thereof are provided. The assembled subway station includes a plurality of components combined in a ring shape, comprising a bottom plate component, two bottom corner components, two side wall components, a middle plate component, two top corner components, and a top plate component. Connection surfaces of each component are each provided with a concave-convex structure being matched with another concave-convex structure on a relevant connection surface of an adjacent component. Butt joint positions of two adjacent components are filled with sealing structures. The embedded grooves of two adjacent components are oppositely arranged, and connecting members for exerting opposite fastening forces on the two adjacent components are installed in the oppositely arranged embedded grooves.

Abstract: A display device and a dimming device are provided. A dimming layer is located between a first polarizer and a second polarizer whose transmission axes are parallel to each other. When the display device is in a first display mode, long axes of the liquid crystal molecules distributed in the first polymer network are arranged along the second direction, and long axis of the liquid crystal molecules distributed in the second polymer network are arranged along the third direction. The third direction and the second direction respectively point to opposite sides of a normal line of the first polarizer.

Abstract: This disclosure provides techniques for automatically generating a geometric representation based on a system-level model (e.g., a lumped parameter model, or LPM). The geometric representation may include a three-dimensional (3D) or cross-sectional shape, resulting from topology optimization within a design space automatically generated without human intervention. An example method may include identifying one or more constraints for each of two or more components of an LPM. One or more conditions are generated for the LPM. The one or more conditions are mapped to the one or more constraints. A processing device may generate a design space for a geometric representation to perform functions represented by the LPM. The geometric representation is subject to the generated one or more conditions. The processing device may then perform topology optimization of the geometric representation in the design space to generate an optimized geometry (e.g., a converged and/or final output).

Abstract: Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.

Abstract: The present disclosure provides techniques for automatically modifying shape features related to overhangs such that support structures can be reduced or avoided. In an example, a shape modification processing device may obtain an initial shape and relevant production information (e.g., overhang angle threshold). The shape modification processing device may modify the shape to improve various aspects of production, including reduction or removal of the need for support materials or structures during additive manufacturing, with considerations that allow the modified portion (e.g., added features) be accessible for removal by subtractive manufacturing. For example, the shape modification processing device may modify a model to reduce or remove support structures needed during production. The added features may later be removed by subtractive manufacturing to restore any functional or desired shape.

Abstract: Several approaches to produce, isolate, and characterize exosomes recovered from a cultivated placenta or a portion thereof are provided. The alternatives described herein facilitate the production, isolation, and characterization of exosomes, which can be used as biotechnological tools and therapeutics. Also provided herein are populations of exosomes derived from placenta organ culture or culture of portions of the placenta. Also provided are compositions comprising the populatons of exosomes and methods of their use for the treatment of subjects.

Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.

Abstract: Provided herein are methods of using CD10+, CD34?, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19).

Abstract: The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said population of exosomes is positive for CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4, or combinations thereof. Such diseases, disorders and conditions include lung, liver, central nervous system, kidney, cardiovascular, gastrointestinal, spleen, eye, systemic and ageing associated diseases, disorders, and conditions.

Abstract: An automatic human urine detection system comprises a control module, a urine collection module, a detection module, an output module and a cleaning module. The control module controls operation of the system and comprises an instruction input unit. The urine collecting module is used for collecting urine to be detected; the detection module comprises a detection probe holder which is used for detecting the urine to be collected and obtains a corresponding detection report according to a detection result; the output module is used for outputting the detection report; and the cleaning module is used for cleaning system components through which the urine flows or is stored in the system. The automatic human urine detection system integrates automatic collection and subsequent automatic detection of human urine, the whole urinalysis process is effectively simplified, the operation process is humanized, and the user experience is good.

Abstract: Provided herein are genetically modified (GM) natural killer (NK) cells and methods of producing populations of GM NK cells. Further provided herein are methods of using the GM NK cells described herein, to, e.g., suppress the proliferation of tumor cells, or to inhibit pathogen infection, e.g., viral infection. In certain alternatives, GM NK cells provided herein lack expression of CBLB, NKG2A and/or TGFBR2 and/or function or show reduced expression and/or function of CBLB, NKG2A and/or TGFBR2. In certain alternatives, GM NK cells provided herein comprise modified CD16.

Abstract: The present invention provides an isolated non-human placenta derived stem cell, wherein the stem cell expresses CD90 or wherein the stem cell expresses CD29. The present invention also provides a composition comprising an isolated non-human placenta derived stem cell of the invention or a population of isolated non-human placenta derived stem cells of the invention, and a carrier. The present invention also provides a composition of the invention for use in the manufacture of a medicament to reduce the incidence of rejection in a patient receiving a xenotransplant form a non-human donor. The present invention provides a method of treating a subject receiving a xenotransplant or xenotransfusion comprising the step of administering to the patient an effective amount of a non-human placenta derived stem cells.

Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.

Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.